MCHM3001 · From Molecules to Therapeutics
Cell Models & Antibody Discovery
Lectures 7–8 of MCHM3001 cover the biological test systems that sit between a molecule and a patient — 2D and 3D cultures, organoids and organ-on-a-chip — and the discovery of antibody drugs through natural diversity generation and display selection. The examinable core is why 3D models are more predictive, how antibody diversity arises (V(D)J recombination plus somatic hypermutation), and how phage display exploits the genotype-phenotype link. It appears in Test 1 and the final.
What this chapter covers
- 012D culture: adherent monolayers, media requirements, confluency, contact inhibition and passaging; immortal cancer lines
- 02Caco-2 (intestinal permeability, P-gp) and hepatic models (HepG2/HepaRG) for absorption and metabolism assays
- 032D vs 3D: gradients, adhesions and stiffness; scaffolded vs scaffold-free spheroids; organoids from iPSCs (Yamanaka factors Oct4/Sox2/Klf4/c-Myc)
- 04Organ-on-a-chip microfluidics linking organs (e.g. liver + tumour to show metabolism-dependent toxicity)
- 05Phenotypic versus target-based screening and their trade-offs
- 06Antibody diversity: V(D)J recombination (heavy V+D+J, light V+J; repertoire ~10⁹–10¹¹) then somatic hypermutation (AID) for affinity maturation
- 07Protein display as a genotype-phenotype link; platform library sizes (phage 10¹¹⁻¹², yeast 10⁹, ribosome 10¹²⁻¹⁵)
- 08Phage display and biopanning (bind/wash/elute/amplify); humanisation ladder (mouse → chimeric → humanised → human, e.g. adalimumab)
How antibody diversity is generated and selected
- +1Primary diversity: V(D)J recombination assembles the antigen-binding region — the heavy chain from V, D and J gene segments and the light chain from V and J — generating a naive repertoire of roughly 10⁹–10¹¹ distinct antibodies.
- +1Affinity maturation: somatic hypermutation (driven by the enzyme AID) introduces point mutations into the variable region, and higher-affinity binders are selected — sharpening specificity beyond the germline repertoire.
- +1Display and selection: the antibody-fragment library is expressed on phage so each particle carries its own encoding DNA (the genotype-phenotype link); biopanning then iterates bind → wash → elute → amplify against the immobilised antigen to enrich the most avid binders, whose genes are recovered from the winning phage.
- +1Why antibodies can out-specify small molecules: they engage a large protein-protein interface with many complementary contacts, so they can distinguish closely related epitopes and reach targets (TNF-α, immune checkpoints) that offer no small-molecule pocket.
Key terms
- Caco-2 monolayer
- A human colon-carcinoma cell line that forms a tight-junction monolayer modelling the intestinal epithelium; used to assay oral absorption/permeability and P-glycoprotein efflux.
- 3D culture / organoid
- A three-dimensional model (scaffolded hydrogel or scaffold-free spheroid) that restores gradients, native adhesions and tissue-like stiffness; organoids are self-organising mini-organs grown from iPSCs, more physiologically predictive than 2D.
- Organ-on-a-chip
- A microfluidic device linking miniature tissues (e.g. liver and tumour) to reproduce inter-organ effects such as metabolism-dependent drug toxicity.
- V(D)J recombination
- The somatic assembly of antibody variable regions from V, D and J gene segments (heavy chain) or V and J (light chain), generating a naive repertoire of ~10⁹–10¹¹ antibodies.
- Somatic hypermutation
- AID-driven point mutation of the antibody variable region that, with selection, matures affinity for the antigen beyond the germline repertoire.
- Phage display / biopanning
- Expressing a protein library on phage so genotype (DNA inside) and phenotype (protein outside) stay linked; biopanning iterates bind/wash/elute/amplify to enrich and then recover the tightest binder.
Cell Models & Antibody Discovery FAQ
Why are 3D cultures considered more predictive than 2D monolayers?
A 2D monolayer forces cells into an unnatural flat, polarised sheet on stiff plastic, whereas 3D models restore soluble gradients, three-dimensional cell-cell and cell-matrix adhesions, and tissue-like (kPa, not GPa) stiffness. Organoids grown from iPSCs even self-organise into mini-organ architecture. That closer physiology makes 3D systems better at predicting how a drug will behave in tissue, at the cost of complexity.
What is the difference between V(D)J recombination and somatic hypermutation?
They act in sequence. V(D)J recombination is the combinatorial assembly of the antibody variable region from gene segments, which creates the enormous naive repertoire (~10⁹–10¹¹). Somatic hypermutation happens afterwards, once an antibody has met its antigen: the enzyme AID introduces point mutations and selection keeps the higher-affinity variants, maturing the response. One builds diversity; the other refines it.
How does phage display find a binder without knowing the answer in advance?
It keeps each antibody physically tied to the DNA that encodes it (the genotype-phenotype link) by displaying the protein on the phage surface. You then run biopanning — expose the whole library to the immobilised antigen, wash away non-binders, elute and amplify the binders, and repeat. Each round enriches the tightest binders, and at the end you sequence the winning phage to read off the antibody.
Can AI help me with the cell-models and antibody material in MCHM3001?
Yes. Sia can contrast 2D, 3D and organ-on-a-chip systems, explain the sequence of V(D)J recombination then somatic hypermutation, walk through a biopanning cycle, or drill the humanisation ladder from mouse to fully human antibody. It explains the biology and checks your reasoning; it does not do graded assessment for you, and University of Sydney academic-integrity rules apply.
Exam move
Treat this chapter as two comparison tables you can reproduce under pressure. First, biological models: 2D versus 3D versus organ-on-a-chip, scored on physiology, gradients, adhesions and stiffness, with Caco-2 and hepatic lines pinned to what they assay. Second, antibody discovery: the two-stage diversity engine (V(D)J then somatic hypermutation), the display platforms ranked by library size, and the humanisation ladder. Be ready to explain, in a sentence, why an antibody can out-specify a small molecule. When the display platforms or Yamanaka factors slip, ask Sia to quiz you on them as flashcards.
Working through Cell Models & Antibody Discovery in MCHM3001? Sia is AskSia’s AI Chemistry tutor — ask any MCHM3001 Cell Models & Antibody Discovery question and get a clear, step-by-step explanation grounded in how MCHM3001 is taught and assessed. Read this chapter free, then take your hardest questions to Sia.
